Experts Caution Against Weight-Loss Injections as PMOS Cure, Stress Individualised Plans

Weight-loss injections, particularly those belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, are gaining significant attention for weight management. However, specialists are cautioning that these medicines are not a cure for Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as PCOS, and should not be used without stringent medical supervision, according to ET Healthworld.

Dr. Hrishikesh Pai, Gynaecologist and IVF Specialist and Medical Director at Bloom IVF Group, emphasized that weight-loss injections should not be viewed as a universal treatment for PMOS, which is a complex hormonal and metabolic condition. While weight reduction can improve metabolic health and menstrual regularity in some women, it does not address the underlying disorder. Treatment, Dr. Pai noted, must target a woman's specific symptoms and long-term health needs, rather than focusing solely on weight.

GLP-1 medicines work by regulating appetite, satiety, and blood sugar levels. They are typically prescribed for type 2 diabetes or weight management in eligible patients, but PMOS itself is not an established standalone indication. The 2023 international evidence-based PCOS guideline suggests that anti-obesity drugs, including semaglutide and liraglutide, may be considered for adults with PCOS and higher weight, provided they align with general obesity-management guidelines and are used alongside lifestyle interventions.

Endocrinologist Dr. Kunal Gupta, consultant at SPARSH Hospital, Bangalore, highlighted the necessity of a thorough assessment before prescribing these medicines. This includes evaluating body weight, blood sugar levels, insulin resistance, and other associated risk factors. Dr. Gupta stressed that not every woman with PMOS requires a weight-loss drug, and the diagnosis alone is not a sufficient reason to initiate injections. Doctors must confirm that the patient meets the criteria for pharmacological weight management and openly discuss expected benefits, potential adverse effects, and alternative treatments. These medicines, he added, should complement appropriate nutrition, physical activity, and follow-up care, not replace them.

Dr. Gupta also cautioned that the benefits of GLP-1 medicines might not persist after treatment discontinuation, especially if sustainable lifestyle changes and long-term weight-management strategies are not in place. Weight regain can occur as the appetite-suppressing effects diminish. He advised that doctors should proactively plan how weight and metabolic health will be monitored if treatment is stopped, rather than allowing patients to discontinue or restart the drug independently. Dr. Nehal Dhaduk, Consultant Gynaecology at PB Health, Gurugram, echoed this, stating that women should be counselled about the possibility of weight regain before starting treatment and should maintain continuous communication with their doctors for long-term management.

Common side effects associated with GLP-1 medicines include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. Dr. Dhaduk also warned of more serious complications, such as gallbladder problems or pancreatitis, underscoring the critical need for medical supervision to assess risks, select the appropriate medicine, and monitor treatment efficacy and safety.

Pregnancy planning is another vital consideration, as improvements in metabolic health and ovulation can increase conception chances for some women with PMOS. Dr. Megha Mittal, Senior Consultant, Obstetrics and Gynaecology, Apollo Spectra Hospital Delhi, advised that women planning pregnancy must discuss these medicines with their doctors prior to starting treatment. These drugs should not be used for weight loss during pregnancy, and the recommended interval between stopping treatment and attempting conception varies by medicine; for instance, semaglutide should be discontinued at least two months before a planned pregnancy. She also emphasized the importance of discussing contraception and preconception care with a gynaecologist.

Dr. Mittal further underlined that comprehensive PMOS management should address menstrual health, fertility goals, mental well-being, and metabolic risks, including type 2 diabetes. Depending on individual symptoms and clinical assessment, treatment may involve lifestyle interventions, hormonal contraceptives, metformin, or fertility treatments. Experts collectively stressed that the ultimate goal should be sustainable weight management and long-term health, rather than rapid weight loss achieved through unsupervised medication.

What to watch: Ongoing research into PMOS treatments

Editor's note: The draft is comprehensive, covers all expert perspectives provided in the source, and accurately summarizes the medical advice and warnings regarding PMOS and weight-loss drugs.